依达拉奉治疗急性脑梗死84例的疗效评价

目的：通过应用依达拉奉治疗急性脑梗死（ACI）观察其临床疗效。方法：将急性脑梗死患者84例随机分为联合组和对照组,每组各42例。治疗组给予治疗脑梗死的基础方案上加用依达拉奉注射剂30mg;对照组给予脑梗死基础治疗方案,两组疗程均为14天。观察两组治疗前及治疗后第1、3、7、14天时对患者进行神经功能缺损评定（采用美国国立卫生研究院卒中量表NIHSS评定）,临床疗效评价和日常生活能力（Barthel指数,BI）评分,并同时监测肝肾功能、血尿常规、血脂、血糖和心电图。结果：两组治疗后NIHSS评分和BI评分均有明显改善。与对照组相比,均在第3天治疗组明显改善（P〈0.05）,第7天和第14天也有明显的改善差异（P〈0.001）;两组治疗后,临床疗效评价也有明显变化,治疗组优于对照组。结论：依达拉奉治疗急性脑梗死临床疗效显著,且安全性高,明显降低病死率,改善神经功能缺损。

Therapeutic effect of Edaravone on the 84 patients with acute Cerebral Infarction

Objective:To evaluate the clinical efficacy of Edaravone on the treatment of acute cerebral infarction.Methods:84 patients with acute cerebral infarction (ACI)were randomlydivided intotwogroups:the treatment group and the control group,42 cases in each group.Edaravone(30mg)was executed in treatment group besides the basic scheme to treat infarction for 14 days,and the latter was just executed in control group exclusively for 14 days.Before and 1d,7d,14d and 2ld after the therapy,neural function defect evaluation (NIHSS)and the Bathals: index (BI)were assessed;and than clinical curative effect were measured at prior treatment and post treatment in both groups.The liver and renal function,blood and urinaryroutine,lipid,glucose and electrocardiogram (ECG)were detected.Result There was a significant improvement of the outcome of NIHSS and BI in the two1groups.The treatment group had obvious amelioration at the 3rd daythan the control group byNIHSSand BI (P<0.05),and exceedingsignificant difference at the 7th dayand the 14th day (P<0.001).Clinical outcome of the two groups on the clinical curative efficacy was greatly improved.The treatment group was better than the control group (P<0.05).Conclusions: Clinical efficacyin treatingACI with edaravone is significant and safety,which can significantlyreduce the mortalityand improve the neurological deficit.